Aptevo Offloads Ruxience Biosimilar Rights In $67.5m Deal
Aptevo currently receives a 2.5% royalty from Pfizer
The royalties for Pfizer’s Ruxience biosimilar, which has achieved a near 25% penetration rate in the US market, are to fall into the hands of another party following an agreement by original holder Aptevo Therapeutics. Teva’s Truxima is reported to be market leader in the US.
